5/30
01:19 am
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/29
04:01 pm
glyc
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
Medium
Report
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
5/22
03:06 am
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/22
03:06 am
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/15
12:06 am
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
5/8
07:57 am
glyc
Uproleselan's failed Phase III AML trial shakes up GlycoMimetics' future [Yahoo! Finance]
Low
Report
Uproleselan's failed Phase III AML trial shakes up GlycoMimetics' future [Yahoo! Finance]
5/8
06:21 am
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at Capital One Financial Co. from an "overweight" rating to an "equal weight" rating.
Low
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at Capital One Financial Co. from an "overweight" rating to an "equal weight" rating.
5/7
05:49 am
glyc
GlycoMimetics reports data from Phase III AML treatment trial [Yahoo! Finance]
High
Report
GlycoMimetics reports data from Phase III AML treatment trial [Yahoo! Finance]
4/28
10:44 am
glyc
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate [Yahoo! Finance]
4/25
07:00 am
glyc
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
Medium
Report
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
4/1
09:20 am
glyc
Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Low
Report
Loss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
3/28
10:22 am
glyc
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/28
07:09 am
glyc
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results [Yahoo! Finance]
Medium
Report
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results [Yahoo! Finance]
3/27
02:11 pm
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Medium
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
3/27
07:24 am
glyc
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 [Yahoo! Finance]
Medium
Report
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 [Yahoo! Finance]
3/27
07:00 am
glyc
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
Medium
Report
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
3/21
05:49 pm
glyc
GlycoMimetics Can Become A Game Changer In Blood Cancers [Seeking Alpha]
Low
Report
GlycoMimetics Can Become A Game Changer In Blood Cancers [Seeking Alpha]
3/21
10:35 am
glyc
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? [Yahoo! Finance]
Medium
Report
Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? [Yahoo! Finance]
3/14
11:06 pm
glyc
GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
GlycoMimetics, Inc. (NASDAQ: GLYC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/13
07:00 am
glyc
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
Low
Report
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
3/4
09:57 am
glyc
Positive Signs As Multiple Insiders Buy GlycoMimetics Stock [Yahoo! Finance]
Low
Report
Positive Signs As Multiple Insiders Buy GlycoMimetics Stock [Yahoo! Finance]